Early access of novel technology that enables
preparation of thousands of samples at low cost through
self-normalization, enhanced multiplexing, and streamlined
workflow
Innovative solution positioned to drive NGS
adoption in AgBio
Twist Flex Prep UHT Kit and additional NGS
tools to be highlighted at AGBT General Meeting
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced technology early
access of the Twist Flex Prep Ultra High-Throughput (UHT) Kit,
which aims to enable unparalleled throughput at a fraction of the
cost of existing on market solutions, accelerating NGS’ microarray
conversion and adoption in agricultural genomics.
Built upon enzymatic fragmentation library preparation, the
Twist Flex Prep UHT Kit utilizes novel chemistry that accepts and
self-normalizes a wide range of sample input amounts through a new
proprietary Normalization By Ligation (NBL) technology. This is
crucial for researchers in AgBio who sequence thousands of samples
of varying inputs and removes the need to manually normalize each
one, saving significant time and costs. The kit also enables
enhanced multiplexing by pooling samples early in the workflow so
that researchers can process more samples without additional
capital investment. The enhanced multiplexing further limits hands
on time and saves researchers costs of reagents in downstream
purification and indexing steps. In addition, pooling samples
significantly reduces cost and plastic waste from pipette tips and
plates in high-throughput labs.
“In agricultural genomics, researchers often test thousands of
samples at once, relying heavily on automation to support large
scale testing. Many researchers continue to perform traditional
microarray based workflows, as overall higher cost per sample for
NGS based workflow has hindered adoption,” said Emily M. Leproust,
Ph.D., CEO and co-founder of Twist Bioscience. “With the technology
early access of our Twist Flex Prep UHT Kit, researchers will soon
have access to a scalable, streamlined, and most importantly, cost
effective NGS workflows for their various samples and research
areas, and overcome the challenges that have caused slow adoption
of NGS in the AgBio space. This ultra high-throughput solution
could enable them to push new boundaries in breeding, trait
selection, and other high-throughput applications, with high data
quality while saving costs.”
Twist Flex Prep UHT Kit Workflow
The Twist Flex Prep UHT Kit workflow is purpose-built to
streamline and massively scale up Twist’s established enzymatic
fragmentation methods. The new NBL technology eliminates the need
to measure quantity of each DNA sample and to perform time
consuming concentration adjustment prior to library preparation,
saving significant cost per sample. Following fragmentation and
adapter ligation of each sample in a plate, up to 48 samples are
pooled together in a single tube. This pooling strategy results in
a meaningful reduction in both volumes and costs of reagents
required for subsequent beads purification and amplification steps.
Libraries prepared from this kit can be leveraged to perform
standard whole genome sequencing (WGS), target enrichment, or
low-pass WGS with enrichment.
By combining up to 48 unique adapters from the Twist UHT Flex
Prep Kit with Twist’s current high throughput Unique Dual Indexing
(UDI) system, theoretical sample multiplexing can top more than
140,000. All plate and tube formats are optimized to ensure
compatibility with key automation systems, a critical consideration
for labs looking to streamline workflows and reduce hands-on
time.
Presence at Advances in Genome Biology and Technology (AGBT)
General Meeting
Twist will highlight its NGS tools in posters and presentations
at the AGBT General Meeting taking place in Orlando, FL February
5-8, 2024. Details are as follows:
Poster: Twist Pan-Cancer Reference Standards V2: Enhanced
Precision and Reduced Errors in ctDNA Analysis Time: Tuesday,
February 6, 1:30-3:30 PM ET
Presentation: Unveiling Next-Gen Solutions for Precision
Diagnostics and Beyond Speaker: Emily M. Leproust, CEO and
co-founder of Twist Bioscience Time: Wednesday, February 7,
3:00-3:20 PM PT Location: Palms Ballroom 2 & 3
Poster: Development of a high-throughput NGS library preparation
workflow with normalization adapters and in-line barcode technology
Time: Wednesday, February 7, 4:45-6:10 PM ET
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube |
Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
ability of the Twist Flex Prep UHT Kit to enable unparalleled
throughput at a fraction of the cost of existing on market
solutions, save researchers significant time and costs, and enable
them to push new boundaries in breeding, trait selection, and other
high-throughput applications. Forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the ability to achieve the expected benefits of Twist
Bioscience’s restructuring activities and reduced investments in
DNA data storage; the ability to attract new customers and retain
and grow sales from existing customers; the ability of Twist
Bioscience to achieve sufficient revenue to achieve or maintain
positive cash flow from operations or profitability in any given
period; risks and uncertainties of rapidly changing technologies
and extensive competition in synthetic biology that could make the
products Twist Bioscience is developing obsolete or
non-competitive; uncertainties of the retention of significant
customers; the ability of Twist Bioscience to successfully
integrate acquired companies and to achieve expected benefits from
acquisitions; supply chain and other disruptions; risks of third
party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on February
2, 2024 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240205346726/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Grafico Azioni Twist Bioscience (NASDAQ:TWST)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Twist Bioscience (NASDAQ:TWST)
Storico
Da Set 2023 a Set 2024